This is a StreetInsider.com Premium Only Page

Aytu BioScience (AYTU) – Accesswire

Apr 3, 2024 09:00 AM Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Feb 14, 2024 04:05 PM Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Feb 7, 2024 04:15 PM Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

Jan 23, 2024 09:00 AM Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Nov 30, 2023 08:00 AM Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Nov 14, 2023 04:05 PM Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Nov 8, 2023 08:30 AM Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Nov 7, 2023 04:15 PM Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

Oct 26, 2023 08:00 AM Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Oct 9, 2023 04:15 PM Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

Sep 26, 2023 08:27 PM Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

Sep 21, 2023 08:25 PM Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023

Sep 13, 2023 08:00 AM Aytu BioPharma to Present at LD Micro Main Event XVI Conference

Jul 31, 2023 08:00 AM Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority

Jul 10, 2023 08:00 AM Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Jun 14, 2023 08:00 AM Aytu to Participate in the Maxim Group Virtual Healthcare Conference

Jun 13, 2023 01:45 PM Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market

Jun 9, 2023 08:00 AM Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director

May 11, 2023 04:05 PM Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results

May 4, 2023 04:30 PM Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023

May 1, 2023 08:00 AM Aytu BioPharma Subleases a Portion of Its Manufacturing Facility

Apr 27, 2023 08:00 AM Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer

Feb 21, 2023 04:10 PM Aytu BioPharma Reports Second Quarter of Fiscal Year 2023

Feb 21, 2023 03:00 PM Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023

Feb 14, 2023 08:00 AM Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results

Feb 7, 2023 08:00 AM Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023

Jan 25, 2023 08:00 AM Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance

Jan 24, 2023 08:00 AM Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31

Jan 10, 2023 08:00 AM Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients

Jan 5, 2023 04:01 PM Aytu BioPharma Announces 1-for-20 Reverse Stock Split

Nov 30, 2022 08:00 AM Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect

Nov 22, 2022 04:05 PM Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Nov 17, 2022 08:00 AM Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row

Nov 16, 2022 08:00 AM Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso

Nov 14, 2022 04:05 PM Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023

Nov 7, 2022 04:01 PM Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022

Oct 25, 2022 08:00 AM Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan

Oct 13, 2022 08:00 AM Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs

Oct 5, 2022 08:00 AM Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions

Sep 27, 2022 04:05 PM Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue

Sep 20, 2022 08:00 AM Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022

Sep 14, 2022 08:00 AM Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin

Aug 24, 2022 08:00 AM Aytu BioPharma to Participate in September 2022 Investor Conferences

Aug 16, 2022 08:00 AM Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin

Aug 15, 2022 04:01 PM Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering

Aug 9, 2022 09:15 AM Aytu BioPharma Announces Pricing of Public Offering

Aug 8, 2022 04:01 PM Aytu BioPharma Announces Launch of Public Offering

Jul 26, 2022 08:00 AM Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Jul 20, 2022 08:00 AM Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome

Jun 29, 2022 08:00 AM Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors